Compare DSY & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | SKYE |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 24.7M |
| IPO Year | 2023 | 2013 |
| Metric | DSY | SKYE |
|---|---|---|
| Price | $4.34 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 4.4M | 117.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.57 |
| 52 Week High | $19.90 | $4.99 |
| Indicator | DSY | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 46.91 |
| Support Level | $1.88 | $0.69 |
| Resistance Level | $19.90 | $0.84 |
| Average True Range (ATR) | 0.48 | 0.04 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 73.53 | 49.18 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.